Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia
- PMID: 29241908
- DOI: 10.1016/j.tjog.2017.10.002
Laboratory and clinical significance of macroprolactinemia in women with hyperprolactinemia
Abstract
The role of macroprolactinemia in women with hyperprolactinemia is currently controversial and can lead to clinical dilemmas, depending upon the origin of macroprolactin, the presence of hyperprolactinemic symptoms and monomeric prolactin (PRL) levels. Macroprolactinemia is mostly considered an extrapituitary phenomenon of mild and asymptomatic hyperprolactinemia associated with normal concentrations of monomeric PRL and a predominance of macroprolactin confined to the vascular system, which is biologically inactive. Patients can therefore be reassured that macroprolactinemia should be considered a benign clinical condition, resistant to antiprolactinemic drugs, and that no diagnostic investigations or prolonged follow-up should be necessary. However, a significant proportion of macroprolactinemic patients appears to suffer from hyperprolactinemia-related symptoms and radiological pituitary findings commonly associated with true hyperprolactinemia. The symptoms of hyperprolactinemia are correlated to the levels of monomeric PRL excess, which may be explained as coincidental, by dissociation of macroprolactin, or by physiological, pharmacological and pathological causes. The excess of monomeric PRL levels in such cases is of primarily importance and the diagnosis of macroprolactinemia is misleading or inadequate. However, macroprolactinemia of pituitary origin associated with radiological findings of pituitary adenomas may rarely occur with similar hyperprolactinemic manifestations, exclusively due to bioactivity of macroprolactin. Therefore, in such cases with hyperprolactinemic signs and pituitary findings, macroprolactinemia should be considered a pathological biochemical condition of hyperprolactinemia. Accordingly, individualized diagnostic investigations with the introduction of dopamine agonists, or other treatment with prolonged follow-up, should be mandatory. The review analyses the laboratory and clinical significance of macroprolactinemia in hyperprolactinemic women suggesting clinically useful diagnostic and treatment strategies.
Keywords: Hyperprolactinemia; Macroprolactin; Macroprolactinemia; Prolactin.
Copyright © 2017. Published by Elsevier B.V.
Similar articles
-
Importance of macroprolactinemia in hyperprolactinemia.Eur J Obstet Gynecol Reprod Biol. 2014 Dec;183:28-32. doi: 10.1016/j.ejogrb.2014.10.013. Epub 2014 Oct 20. Eur J Obstet Gynecol Reprod Biol. 2014. PMID: 25461348 Review.
-
[Macroprolactinemia in the differential diagnosis of hyperprolactinemia].Orv Hetil. 2003 Oct 26;144(43):2121-7. Orv Hetil. 2003. PMID: 14661444 Hungarian.
-
Clinical and laboratory features greatly overlap in patients with macroprolactinemia or monomeric hyperprolactinemia.Minerva Endocrinol. 2007 Jun;32(2):79-86. Minerva Endocrinol. 2007. PMID: 17557033
-
Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia.Clin Chem. 2003 Sep;49(9):1504-9. doi: 10.1373/49.9.1504. Clin Chem. 2003. PMID: 12928232
-
Macroprolactinemia: new insights in hyperprolactinemia.Biochem Med (Zagreb). 2012;22(2):171-9. doi: 10.11613/bm.2012.020. Biochem Med (Zagreb). 2012. PMID: 22838183 Free PMC article. Review.
Cited by
-
Evaluation of autoantibodies and immunoglobulin G subclasses in women with suspected macroprolactinemia.J Clin Lab Anal. 2020 Nov;34(11):e23456. doi: 10.1002/jcla.23456. Epub 2020 Jun 29. J Clin Lab Anal. 2020. PMID: 32597541 Free PMC article.
-
The Correlation Between DRD2 and COMT Gene Polymorphisms, HPT and HPG Axes Functions, and Antipsychotic Drug-Induced Hyperprolactinemia and Macroprolactinemia.Neuropsychiatr Dis Treat. 2025 May 8;21:1011-1017. doi: 10.2147/NDT.S518275. eCollection 2025. Neuropsychiatr Dis Treat. 2025. PMID: 40356870 Free PMC article. Clinical Trial.
-
Optimizing laboratory defined macroprolactin algorithm.Biochem Med (Zagreb). 2019 Jun 15;29(2):020706. doi: 10.11613/BM.2019.020706. Biochem Med (Zagreb). 2019. PMID: 31223260 Free PMC article.
-
Current Insights in Prolactin Signaling and Ovulatory Function.Int J Mol Sci. 2024 Feb 6;25(4):1976. doi: 10.3390/ijms25041976. Int J Mol Sci. 2024. PMID: 38396659 Free PMC article. Review.
-
Prevalence of Macroprolactinemia in People Detected to Have Hyperprolactinemia.J Lab Physicians. 2021 Jul 12;13(4):353-357. doi: 10.1055/s-0041-1732490. eCollection 2021 Dec. J Lab Physicians. 2021. PMID: 34975255 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources